GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00434016 | Liver | NAFLD | steroid hormone mediated signaling pathway | 28/1882 | 136/18723 | 1.78e-04 | 3.14e-03 | 28 |
GO:00488133 | Liver | NAFLD | dendrite morphogenesis | 29/1882 | 146/18723 | 2.63e-04 | 4.26e-03 | 29 |
GO:00305185 | Liver | NAFLD | intracellular steroid hormone receptor signaling pathway | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
GO:00431124 | Liver | NAFLD | receptor metabolic process | 31/1882 | 166/18723 | 5.10e-04 | 7.15e-03 | 31 |
GO:00015585 | Liver | NAFLD | regulation of cell growth | 63/1882 | 414/18723 | 5.50e-04 | 7.46e-03 | 63 |
GO:00436207 | Liver | NAFLD | regulation of DNA-templated transcription in response to stress | 14/1882 | 53/18723 | 5.66e-04 | 7.59e-03 | 14 |
GO:00726653 | Liver | NAFLD | protein localization to vacuole | 16/1882 | 67/18723 | 7.94e-04 | 9.90e-03 | 16 |
GO:00726663 | Liver | NAFLD | establishment of protein localization to vacuole | 13/1882 | 49/18723 | 8.43e-04 | 1.03e-02 | 13 |
GO:00714783 | Liver | NAFLD | cellular response to radiation | 33/1882 | 186/18723 | 8.76e-04 | 1.07e-02 | 33 |
GO:00605604 | Liver | NAFLD | developmental growth involved in morphogenesis | 39/1882 | 234/18723 | 1.11e-03 | 1.28e-02 | 39 |
GO:00725947 | Liver | NAFLD | establishment of protein localization to organelle | 62/1882 | 422/18723 | 1.48e-03 | 1.64e-02 | 62 |
GO:00468227 | Liver | NAFLD | regulation of nucleocytoplasmic transport | 21/1882 | 106/18723 | 1.81e-03 | 1.86e-02 | 21 |
GO:00070345 | Liver | NAFLD | vacuolar transport | 28/1882 | 157/18723 | 1.91e-03 | 1.93e-02 | 28 |
GO:19901383 | Liver | NAFLD | neuron projection extension | 30/1882 | 172/18723 | 1.93e-03 | 1.94e-02 | 30 |
GO:00070414 | Liver | NAFLD | lysosomal transport | 22/1882 | 114/18723 | 2.03e-03 | 2.02e-02 | 22 |
GO:00301005 | Liver | NAFLD | regulation of endocytosis | 35/1882 | 211/18723 | 2.09e-03 | 2.06e-02 | 35 |
GO:00109755 | Liver | NAFLD | regulation of neuron projection development | 64/1882 | 445/18723 | 2.12e-03 | 2.08e-02 | 64 |
GO:00162365 | Liver | NAFLD | macroautophagy | 45/1882 | 291/18723 | 2.31e-03 | 2.19e-02 | 45 |
GO:00020286 | Liver | NAFLD | regulation of sodium ion transport | 18/1882 | 90/18723 | 3.34e-03 | 2.93e-02 | 18 |
GO:00515923 | Liver | NAFLD | response to calcium ion | 26/1882 | 149/18723 | 3.69e-03 | 3.15e-02 | 26 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa04530110 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453014 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453015 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NEDD4 | SNV | Missense_Mutation | novel | c.3618N>G | p.Asp1206Glu | p.D1206E | P46934 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
NEDD4 | SNV | Missense_Mutation | | c.3271N>G | p.His1091Asp | p.H1091D | P46934 | protein_coding | deleterious(0.03) | benign(0.05) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | rs547250575 | c.280G>A | p.Glu94Lys | p.E94K | P46934 | protein_coding | deleterious(0.05) | probably_damaging(0.965) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | | c.1361N>A | p.Arg454Gln | p.R454Q | P46934 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NEDD4 | SNV | Missense_Mutation | | c.2611C>T | p.Pro871Ser | p.P871S | P46934 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
NEDD4 | SNV | Missense_Mutation | novel | c.154N>T | p.Met52Leu | p.M52L | P46934 | protein_coding | tolerated(0.3) | benign(0) | TCGA-E2-A576-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
NEDD4 | SNV | Missense_Mutation | rs369468383 | c.358G>T | p.Asp120Tyr | p.D120Y | P46934 | protein_coding | deleterious_low_confidence(0) | benign(0.347) | TCGA-GM-A2DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
NEDD4 | SNV | Missense_Mutation | novel | c.3895G>C | p.Glu1299Gln | p.E1299Q | P46934 | protein_coding | tolerated(0.13) | benign(0.125) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.2747_2748insCCCTGTCTCTACTAAAAATGCAAAAAAAATTAGTTGGG | p.Lys916AsnfsTer26 | p.K916Nfs*26 | P46934 | protein_coding | | | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.38_39insGATATTCTTGTGTTTCAGTGCATTTG | p.Ser14IlefsTer45 | p.S14Ifs*45 | P46934 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |